Key appointments to drive drug discovery and trials

Biopharmaceutical company Enterprise Therapeutics dedicated to the discovery and development of novel therapies to help people with respiratory disease, has appointed Dr Renu Gupta as CMO (Chief Medical Officer) and Dr Janet Hammond as a Non-Executive Director.

Dr Gupta is a physician-scientist and industry leader, with more than 20 years of experience as a CMO, most recently at Promedior, Inc, a member of the Roche Group. For over  30 years she has held various roles within research and development, executive management and as a Board member, including at Global Bio-Pharma, Corbus Pharmaceuticals, Breath Therapeutics, Insmed, Inc, Novartis and Bristol-Myers Squibb (BMS). Dr Gupta has been instrumental in implementing clinical and regulatory strategies and development pathways to advance targets, forming productive private-public sector partnerships. With medical degrees from the University of Zambia, she completed her medical and post-doctoral training at Albert Einstein Medical Center, the Wistar Institute of Anatomy and Biology, the Children's Hospital of Philadelphia and the University of Pennsylvania.

Dr Hammond has over 20 years’ experience in the pharmaceutical industry, during which time she has overseen the development and successful approval of several drugs. She is currently Chief Development Officer at Atea Pharmaceuticals, a Boston-based biotech focused on the development of antiviral drugs for life-threatening infectious diseases. Prior to joining Atea, Janet was Vice President and Head of Infectious Diseases and General Medicine at AbbVie, Inc, and Senior Vice President and Global Head of Infectious Diseases at Hoffmann-la Roche. She obtained her MD and PhD from the University of Cape Town where she specialised in Pulmonary/Critical Care Medicine, holds a Masters in Clinical Investigation from Johns Hopkins University and carried out training in Infectious Diseases at Duke and Johns Hopkins Universities.

Dr John Ford, CEO, Enterprise Therapeutics, said: “We are delighted to welcome Renu as CMO and Janet to the Board. Renu’s successful track record in developing innovative respiratory medicines will be a great asset to the team, while Janet’s extensive experience in driving late-stage clinical development programmes will be an invaluable addition to the Board. Both appointments substantially strengthen our team as we work towards delivering clinical proof of concept for our lead asset ETD001, taking us a step closer to providing an effective therapy for people with cystic fibrosis not benefitting from CFTR modulators.”

More information online